APO Research
Talk to an analyst

APO RESEARCH · REPORT

Medical Nuclide Products

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Medical Nuclide Products Market Analysis and Forecast 2026-2032

23 December 2025214 pages

Choose your research edition.

Industry ResearchMedical Nuclide Products Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Medical Nuclide Products Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Medical Nuclide Products Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medical Nuclide Products Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Medical Nuclide Products Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Medical Nuclide Products market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Medical Nuclide Products is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Medical Nuclide Products is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Medical Nuclide Products is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Medical Nuclide Products is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Medical Nuclide Products include China Isotope & Radiation, Dongcheng Pharma, Eli Lilly, Junan Pharmaceutical, Bayer, Siemens, Q BioMed, Progenics Pharmaceuticals and Polatom, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Medical Nuclide Products, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Medical Nuclide Products, also provides the revenue of main regions and countries. Of the upcoming market potential for Medical Nuclide Products, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Medical Nuclide Products revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Medical Nuclide Products market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Medical Nuclide Products revenue, projected growth trends, production technology, application and end-user industry.

Medical Nuclide Products Segment by Company

China Isotope & Radiation

Dongcheng Pharma

Eli Lilly

Junan Pharmaceutical

Bayer

Siemens

Q BioMed

Progenics Pharmaceuticals

Polatom

NTP Radioisotopes

NRG

Novartis International AG

Nordion

Mundipharma

Monrol

Lantheus Medical Imaging, Inc.

Jubilant Life Sciences

International Isotopes

GE Healthcare

Eckert & Ziegler Strahlen

Curium Pharma

Cardinal Health

Bracco Imaging

Aurobindo Pharma

ANSTO

Acrotech Biopharma.

Medical Nuclide Products Segment by Type

Radiopharmaceuticals

Radioactive Sources

Medical Diagnostic Nuclides

Others

Medical Nuclide Products Segment by Application

Hematological Diseases

Cardiovascular Diseases

Bone and Joint Diseases

Cancer

Others

Medical Nuclide Products Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medical Nuclide Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medical Nuclide Products and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medical Nuclide Products.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Medical Nuclide Products in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Medical Nuclide Products company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Medical Nuclide Products revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Medical Nuclide Products Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Radiopharmaceuticals Major Player Table 3. Radioactive Sources Major Player Table 4. Medical Diagnostic Nuclides Major Player Table 5. Others Major Player Table 6. Global Medical Nuclide Products Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hematological Diseases Major Player Table 8. Cardiovascular Diseases Major Player Table 9. Bone and Joint Diseases Major Player Table 10. Cancer Major Player Table 11. Others Major Player Table 12. Medical Nuclide Products Industry Trends Table 13. Medical Nuclide Products Industry Drivers Table 14. Medical Nuclide Products Industry Opportunities and Challenges Table 15. Medical Nuclide Products Industry Restraints Table 16. Global Medical Nuclide Products Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Medical Nuclide Products Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Medical Nuclide Products Market Share by Region (2021-2026) Table 19. Global Medical Nuclide Products Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Medical Nuclide Products Market Share by Region (2027-2032) Table 21. Global Medical Nuclide Products Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Medical Nuclide Products Revenue Market Share by Players (2021-2026) Table 23. Global Medical Nuclide Products Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Medical Nuclide Products Key Players Headquarters & Area Served Table 25. Global Medical Nuclide Products Players, Product Type & Application Table 26. Global Medical Nuclide Products Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Medical Nuclide Products by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Medical Nuclide Products Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Medical Nuclide Products Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Medical Nuclide Products Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Medical Nuclide Products Revenue Market Share by Type (2021-2026) Table 33. Global Medical Nuclide Products Revenue Market Share by Type (2027-2032) Table 34. Global Medical Nuclide Products Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Medical Nuclide Products Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Medical Nuclide Products Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Medical Nuclide Products Revenue Market Share by Application (2021-2026) Table 38. Global Medical Nuclide Products Revenue Market Share by Application (2027-2032) Table 39. China Isotope & Radiation Company Information Table 40. China Isotope & Radiation Business Overview Table 41. China Isotope & Radiation Medical Nuclide Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. China Isotope & Radiation Medical Nuclide Products Product Portfolio Table 43. China Isotope & Radiation Recent Development Table 44. Dongcheng Pharma Company Information Table 45. Dongcheng Pharma Business Overview Table 46. Dongcheng Pharma Medical Nuclide Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Dongcheng Pharma Medical Nuclide Products Product Portfolio Table 48. Dongcheng Pharma Recent Development Table 49. Eli Lilly Company Information Table 50. Eli Lilly Business Overview Table 51. Eli Lilly Medical Nuclide Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Eli Lilly Medical Nuclide Products Product Portfolio Table 53. Eli Lilly Recent Development Table 54. Junan Pharmaceutical Company Information Table 55. Junan Pharmaceutical Business Overview Table 56. Junan Pharmaceutical Medical Nuclide Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Junan Pharmaceutical Medical Nuclide Products Product Portfolio Table 58. Junan Pharmaceutical Recent Development Table 59. Bayer Company Information Table 60. Bayer Business Overview Table 61. Bayer Medical Nuclide Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Bayer Medical Nuclide Products Product Portfolio Table 63. Bayer Recent Development Table 64. Siemens Company Information Table 65. Siemens Business Overview Table 66. Siemens Medical Nuclide Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Siemens Medical Nuclide Products Product Portfolio Table 68. Siemens Recent Development Table 69. Q BioMed Company Information Table 70. Q BioMed Business Overview Table 71. Q BioMed Medical Nuclide Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Q BioMed Medical Nuclide Products Product Portfolio Table 73. Q BioMed Recent Development Table 74. Progenics Pharmaceuticals Company Information Table 75. Progenics Pharmaceuticals Business Overview Table 76. Progenics Pharmaceuticals Medical Nuclide Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Progenics Pharmaceuticals Medical Nuclide Products Product Portfolio Table 78. Progenics Pharmaceuticals Recent Development Table 79. Polatom Company Information Table 80. Polatom Business Overview Table 81. Polatom Medical Nuclide Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Polatom Medical Nuclide Products Product Portfolio Table 83. Polatom Recent Development Table 84. NTP Radioisotopes Company Information Table 85. NTP Radioisotopes Business Overview Table 86. NTP Radioisotopes Medical Nuclide Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. NTP Radioisotopes Medical Nuclide Products Product Portfolio Table 88. NTP Radioisotopes Recent Development Table 89. NRG Company Information Table 90. NRG Business Overview Table 91. NRG Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. NRG Medical Nuclide Products Product Portfolio Table 93. NRG Recent Development Table 94. Novartis International AG Company Information Table 95. Novartis International AG Business Overview Table 96. Novartis International AG Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Novartis International AG Medical Nuclide Products Product Portfolio Table 98. Novartis International AG Recent Development Table 99. Nordion Company Information Table 100. Nordion Business Overview Table 101. Nordion Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Nordion Medical Nuclide Products Product Portfolio Table 103. Nordion Recent Development Table 104. Mundipharma Company Information Table 105. Mundipharma Business Overview Table 106. Mundipharma Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Mundipharma Medical Nuclide Products Product Portfolio Table 108. Mundipharma Recent Development Table 109. Monrol Company Information Table 110. Monrol Business Overview Table 111. Monrol Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Monrol Medical Nuclide Products Product Portfolio Table 113. Monrol Recent Development Table 114. Lantheus Medical Imaging, Inc. Company Information Table 115. Lantheus Medical Imaging, Inc. Business Overview Table 116. Lantheus Medical Imaging, Inc. Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. Lantheus Medical Imaging, Inc. Medical Nuclide Products Product Portfolio Table 118. Lantheus Medical Imaging, Inc. Recent Development Table 119. Jubilant Life Sciences Company Information Table 120. Jubilant Life Sciences Business Overview Table 121. Jubilant Life Sciences Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. Jubilant Life Sciences Medical Nuclide Products Product Portfolio Table 123. Jubilant Life Sciences Recent Development Table 124. International Isotopes Company Information Table 125. International Isotopes Business Overview Table 126. International Isotopes Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. International Isotopes Medical Nuclide Products Product Portfolio Table 128. International Isotopes Recent Development Table 129. GE Healthcare Company Information Table 130. GE Healthcare Business Overview Table 131. GE Healthcare Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 132. GE Healthcare Medical Nuclide Products Product Portfolio Table 133. GE Healthcare Recent Development Table 134. Eckert & Ziegler Strahlen Company Information Table 135. Eckert & Ziegler Strahlen Business Overview Table 136. Eckert & Ziegler Strahlen Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 137. Eckert & Ziegler Strahlen Medical Nuclide Products Product Portfolio Table 138. Eckert & Ziegler Strahlen Recent Development Table 139. Curium Pharma Company Information Table 140. Curium Pharma Business Overview Table 141. Curium Pharma Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 142. Curium Pharma Medical Nuclide Products Product Portfolio Table 143. Curium Pharma Recent Development Table 144. Cardinal Health Company Information Table 145. Cardinal Health Business Overview Table 146. Cardinal Health Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 147. Cardinal Health Medical Nuclide Products Product Portfolio Table 148. Cardinal Health Recent Development Table 149. Bracco Imaging Company Information Table 150. Bracco Imaging Business Overview Table 151. Bracco Imaging Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 152. Bracco Imaging Medical Nuclide Products Product Portfolio Table 153. Bracco Imaging Recent Development Table 154. Aurobindo Pharma Company Information Table 155. Aurobindo Pharma Business Overview Table 156. Aurobindo Pharma Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 157. Aurobindo Pharma Medical Nuclide Products Product Portfolio Table 158. Aurobindo Pharma Recent Development Table 159. ANSTO Company Information Table 160. ANSTO Business Overview Table 161. ANSTO Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 162. ANSTO Medical Nuclide Products Product Portfolio Table 163. ANSTO Recent Development Table 164. Acrotech Biopharma. Company Information Table 165. Acrotech Biopharma. Business Overview Table 166. Acrotech Biopharma. Medical Nuclide Products Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 167. Acrotech Biopharma. Medical Nuclide Products Product Portfolio Table 168. Acrotech Biopharma. Recent Development Table 169. North America Medical Nuclide Products Revenue by Type (2021-2026) & (US$ Million) Table 170. North America Medical Nuclide Products Revenue by Type (2027-2032) & (US$ Million) Table 171. North America Medical Nuclide Products Revenue by Application (2021-2026) & (US$ Million) Table 172. North America Medical Nuclide Products Revenue by Application (2027-2032) & (US$ Million) Table 173. North America Medical Nuclide Products Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 174. North America Medical Nuclide Products Revenue by Country (2021-2026) & (US$ Million) Table 175. North America Medical Nuclide Products Revenue by Country (US$ Million) & (2027-2032) Table 176. Europe Medical Nuclide Products Revenue by Type (2021-2026) & (US$ Million) Table 177. Europe Medical Nuclide Products Revenue by Type (2027-2032) & (US$ Million) Table 178. Europe Medical Nuclide Products Revenue by Application (2021-2026) & (US$ Million) Table 179. Europe Medical Nuclide Products Revenue by Application (2027-2032) & (US$ Million) Table 180. Europe Medical Nuclide Products Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 181. Europe Medical Nuclide Products Revenue by Country (2021-2026) & (US$ Million) Table 182. Europe Medical Nuclide Products Revenue by Country (US$ Million) & (2027-2032) Table 183. China Medical Nuclide Products Revenue by Type (2021-2026) & (US$ Million) Table 184. China Medical Nuclide Products Revenue by Type (2027-2032) & (US$ Million) Table 185. China Medical Nuclide Products Revenue by Application (2021-2026) & (US$ Million) Table 186. China Medical Nuclide Products Revenue by Application (2027-2032) & (US$ Million) Table 187. Asia Medical Nuclide Products Revenue by Type (2021-2026) & (US$ Million) Table 188. Asia Medical Nuclide Products Revenue by Type (2027-2032) & (US$ Million) Table 189. Asia Medical Nuclide Products Revenue by Application (2021-2026) & (US$ Million) Table 190. Asia Medical Nuclide Products Revenue by Application (2027-2032) & (US$ Million) Table 191. Asia Medical Nuclide Products Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 192. Asia Medical Nuclide Products Revenue by Region (US$ Million) & (2021-2026) Table 193. Asia Medical Nuclide Products Revenue by Region (US$ Million) & (2027-2032) Table 194. SAMEA Medical Nuclide Products Revenue by Type (2021-2026) & (US$ Million) Table 195. SAMEA Medical Nuclide Products Revenue by Type (2027-2032) & (US$ Million) Table 196. SAMEA Medical Nuclide Products Revenue by Application (2021-2026) & (US$ Million) Table 197. SAMEA Medical Nuclide Products Revenue by Application (2027-2032) & (US$ Million) Table 198. SAMEA Medical Nuclide Products Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 199. SAMEA Medical Nuclide Products Revenue by Country (2021-2026) & (US$ Million) Table 200. SAMEA Medical Nuclide Products Revenue by Country (US$ Million) & (2027-2032) Table 201. Research Programs/Design for This Report Table 202. Authors List of This Report Table 203. Secondary Sources Table 204. Primary Sources List of Figures Figure 1. Medical Nuclide Products Image Figure 2. Global Medical Nuclide Products Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Medical Nuclide Products Market Size Share 2021 VS 2025 VS 2032 Figure 4. Radiopharmaceuticals Image Figure 5. Radioactive Sources Image Figure 6. Medical Diagnostic Nuclides Image Figure 7. Others Image Figure 8. Global Medical Nuclide Products Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Medical Nuclide Products Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hematological Diseases Image Figure 11. Cardiovascular Diseases Image Figure 12. Bone and Joint Diseases Image Figure 13. Cancer Image Figure 14. Others Image Figure 15. Global Medical Nuclide Products Market Size (US$ Million) & (2021-2032) Figure 16. Global Medical Nuclide Products Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Medical Nuclide Products Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Medical Nuclide Products Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Medical Nuclide Products Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Medical Nuclide Products Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Medical Nuclide Products Revenue Market Share by Type (2021-2032) Figure 23. Global Medical Nuclide Products Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Medical Nuclide Products Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Medical Nuclide Products Revenue Market Share by Application (2021-2032) Figure 26. North America Medical Nuclide Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Medical Nuclide Products Revenue Share by Type (2021-2032) Figure 28. North America Medical Nuclide Products Revenue Share by Application (2021-2032) Figure 29. North America Medical Nuclide Products Revenue Share by Country (2021-2032) Figure 30. United States Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Medical Nuclide Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Medical Nuclide Products Revenue Share by Type (2021-2032) Figure 35. Europe Medical Nuclide Products Revenue Share by Application (2021-2032) Figure 36. Europe Medical Nuclide Products Revenue Share by Country (2021-2032) Figure 37. Germany Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Medical Nuclide Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Medical Nuclide Products Revenue Share by Type (2021-2032) Figure 47. China Medical Nuclide Products Revenue Share by Application (2021-2032) Figure 48. Asia Medical Nuclide Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Medical Nuclide Products Revenue Share by Type (2021-2032) Figure 50. Asia Medical Nuclide Products Revenue Share by Application (2021-2032) Figure 51. Asia Medical Nuclide Products Revenue Share by Region (2021-2032) Figure 52. Japan Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Medical Nuclide Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Medical Nuclide Products Revenue Share by Type (2021-2032) Figure 60. SAMEA Medical Nuclide Products Revenue Share by Application (2021-2032) Figure 61. SAMEA Medical Nuclide Products Revenue Share by Country (2021-2032) Figure 62. Brazil Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Medical Nuclide Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Radiopharmaceuticals
  • Radioactive Sources
  • Medical Diagnostic Nuclides
  • Others
Applications
  • Hematological Diseases
  • Cardiovascular Diseases
  • Bone and Joint Diseases
  • Cancer
  • Others
Companies covered
  • China Isotope & Radiation
  • Dongcheng Pharma
  • Eli Lilly
  • Junan Pharmaceutical
  • Bayer
  • Siemens
  • Q BioMed
  • Progenics Pharmaceuticals
  • Polatom
  • NTP Radioisotopes
  • NRG
  • Novartis International AG
  • Nordion
  • Mundipharma
  • Monrol
  • Lantheus Medical Imaging, Inc.
  • Jubilant Life Sciences
  • International Isotopes
  • GE Healthcare
  • Eckert & Ziegler Strahlen
  • Curium Pharma
  • Cardinal Health
  • Bracco Imaging
  • Aurobindo Pharma
  • ANSTO
  • Acrotech Biopharma.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Medical Nuclide Products Market by Type
  3. 1.2.1 Global Medical Nuclide Products Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Radiopharmaceuticals
  5. 1.2.3 Radioactive Sources
  6. 1.2.4 Medical Diagnostic Nuclides
  7. 1.2.5 Others
  8. 1.3 Medical Nuclide Products Market by Application
  9. 1.3.1 Global Medical Nuclide Products Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hematological Diseases
  11. 1.3.3 Cardiovascular Diseases
  12. 1.3.4 Bone and Joint Diseases
  13. 1.3.5 Cancer
  14. 1.3.6 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Medical Nuclide Products Market Dynamics
  1. 2.1 Medical Nuclide Products Industry Trends
  2. 2.2 Medical Nuclide Products Industry Drivers
  3. 2.3 Medical Nuclide Products Industry Opportunities and Challenges
  4. 2.4 Medical Nuclide Products Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Medical Nuclide Products Market Perspective (2021-2032)
  2. 3.2 Global Medical Nuclide Products Growth Trends by Region
  3. 3.2.1 Global Medical Nuclide Products Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Medical Nuclide Products Market Size by Region (2021-2026)
  5. 3.2.3 Global Medical Nuclide Products Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Medical Nuclide Products Revenue by Players
  2. 4.1.1 Global Medical Nuclide Products Revenue by Players (2021-2026)
  3. 4.1.2 Global Medical Nuclide Products Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Medical Nuclide Products Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Medical Nuclide Products Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Medical Nuclide Products Key Players Headquarters & Area Served
  7. 4.4 Global Medical Nuclide Products Players, Product Type & Application
  8. 4.5 Global Medical Nuclide Products Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Medical Nuclide Products Market CR5 and HHI
  11. 4.6.3 2025 Medical Nuclide Products Tier 1, Tier 2, and Tier 3
5 Medical Nuclide Products Market Size by Type
  1. 5.1 Global Medical Nuclide Products Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Medical Nuclide Products Revenue by Type (2021-2032)
  3. 5.3 Global Medical Nuclide Products Revenue Market Share by Type (2021-2032)
6 Medical Nuclide Products Market Size by Application
  1. 6.1 Global Medical Nuclide Products Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Medical Nuclide Products Revenue by Application (2021-2032)
  3. 6.3 Global Medical Nuclide Products Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 China Isotope & Radiation
  2. 7.1.1 China Isotope & Radiation Company Information
  3. 7.1.2 China Isotope & Radiation Business Overview
  4. 7.1.3 China Isotope & Radiation Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  5. 7.1.4 China Isotope & Radiation Medical Nuclide Products Product Portfolio
  6. 7.1.5 China Isotope & Radiation Recent Developments
  7. 7.2 Dongcheng Pharma
  8. 7.2.1 Dongcheng Pharma Company Information
  9. 7.2.2 Dongcheng Pharma Business Overview
  10. 7.2.3 Dongcheng Pharma Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Dongcheng Pharma Medical Nuclide Products Product Portfolio
  12. 7.2.5 Dongcheng Pharma Recent Developments
  13. 7.3 Eli Lilly
  14. 7.3.1 Eli Lilly Company Information
  15. 7.3.2 Eli Lilly Business Overview
  16. 7.3.3 Eli Lilly Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eli Lilly Medical Nuclide Products Product Portfolio
  18. 7.3.5 Eli Lilly Recent Developments
  19. 7.4 Junan Pharmaceutical
  20. 7.4.1 Junan Pharmaceutical Company Information
  21. 7.4.2 Junan Pharmaceutical Business Overview
  22. 7.4.3 Junan Pharmaceutical Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Junan Pharmaceutical Medical Nuclide Products Product Portfolio
  24. 7.4.5 Junan Pharmaceutical Recent Developments
  25. 7.5 Bayer
  26. 7.5.1 Bayer Company Information
  27. 7.5.2 Bayer Business Overview
  28. 7.5.3 Bayer Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bayer Medical Nuclide Products Product Portfolio
  30. 7.5.5 Bayer Recent Developments
  31. 7.6 Siemens
  32. 7.6.1 Siemens Company Information
  33. 7.6.2 Siemens Business Overview
  34. 7.6.3 Siemens Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Siemens Medical Nuclide Products Product Portfolio
  36. 7.6.5 Siemens Recent Developments
  37. 7.7 Q BioMed
  38. 7.7.1 Q BioMed Company Information
  39. 7.7.2 Q BioMed Business Overview
  40. 7.7.3 Q BioMed Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Q BioMed Medical Nuclide Products Product Portfolio
  42. 7.7.5 Q BioMed Recent Developments
  43. 7.8 Progenics Pharmaceuticals
  44. 7.8.1 Progenics Pharmaceuticals Company Information
  45. 7.8.2 Progenics Pharmaceuticals Business Overview
  46. 7.8.3 Progenics Pharmaceuticals Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Progenics Pharmaceuticals Medical Nuclide Products Product Portfolio
  48. 7.8.5 Progenics Pharmaceuticals Recent Developments
  49. 7.9 Polatom
  50. 7.9.1 Polatom Company Information
  51. 7.9.2 Polatom Business Overview
  52. 7.9.3 Polatom Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Polatom Medical Nuclide Products Product Portfolio
  54. 7.9.5 Polatom Recent Developments
  55. 7.10 NTP Radioisotopes
  56. 7.10.1 NTP Radioisotopes Company Information
  57. 7.10.2 NTP Radioisotopes Business Overview
  58. 7.10.3 NTP Radioisotopes Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  59. 7.10.4 NTP Radioisotopes Medical Nuclide Products Product Portfolio
  60. 7.10.5 NTP Radioisotopes Recent Developments
  61. 7.11 NRG
  62. 7.11.1 NRG Company Information
  63. 7.11.2 NRG Business Overview
  64. 7.11.3 NRG Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  65. 7.11.4 NRG Medical Nuclide Products Product Portfolio
  66. 7.11.5 NRG Recent Developments
  67. 7.12 Novartis International AG
  68. 7.12.1 Novartis International AG Company Information
  69. 7.12.2 Novartis International AG Business Overview
  70. 7.12.3 Novartis International AG Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Novartis International AG Medical Nuclide Products Product Portfolio
  72. 7.12.5 Novartis International AG Recent Developments
  73. 7.13 Nordion
  74. 7.13.1 Nordion Company Information
  75. 7.13.2 Nordion Business Overview
  76. 7.13.3 Nordion Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Nordion Medical Nuclide Products Product Portfolio
  78. 7.13.5 Nordion Recent Developments
  79. 7.14 Mundipharma
  80. 7.14.1 Mundipharma Company Information
  81. 7.14.2 Mundipharma Business Overview
  82. 7.14.3 Mundipharma Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Mundipharma Medical Nuclide Products Product Portfolio
  84. 7.14.5 Mundipharma Recent Developments
  85. 7.15 Monrol
  86. 7.15.1 Monrol Company Information
  87. 7.15.2 Monrol Business Overview
  88. 7.15.3 Monrol Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Monrol Medical Nuclide Products Product Portfolio
  90. 7.15.5 Monrol Recent Developments
  91. 7.16 Lantheus Medical Imaging, Inc.
  92. 7.16.1 Lantheus Medical Imaging, Inc. Company Information
  93. 7.16.2 Lantheus Medical Imaging, Inc. Business Overview
  94. 7.16.3 Lantheus Medical Imaging, Inc. Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Lantheus Medical Imaging, Inc. Medical Nuclide Products Product Portfolio
  96. 7.16.5 Lantheus Medical Imaging, Inc. Recent Developments
  97. 7.17 Jubilant Life Sciences
  98. 7.17.1 Jubilant Life Sciences Company Information
  99. 7.17.2 Jubilant Life Sciences Business Overview
  100. 7.17.3 Jubilant Life Sciences Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Jubilant Life Sciences Medical Nuclide Products Product Portfolio
  102. 7.17.5 Jubilant Life Sciences Recent Developments
  103. 7.18 International Isotopes
  104. 7.18.1 International Isotopes Company Information
  105. 7.18.2 International Isotopes Business Overview
  106. 7.18.3 International Isotopes Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  107. 7.18.4 International Isotopes Medical Nuclide Products Product Portfolio
  108. 7.18.5 International Isotopes Recent Developments
  109. 7.19 GE Healthcare
  110. 7.19.1 GE Healthcare Company Information
  111. 7.19.2 GE Healthcare Business Overview
  112. 7.19.3 GE Healthcare Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  113. 7.19.4 GE Healthcare Medical Nuclide Products Product Portfolio
  114. 7.19.5 GE Healthcare Recent Developments
  115. 7.20 Eckert & Ziegler Strahlen
  116. 7.20.1 Eckert & Ziegler Strahlen Company Information
  117. 7.20.2 Eckert & Ziegler Strahlen Business Overview
  118. 7.20.3 Eckert & Ziegler Strahlen Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Eckert & Ziegler Strahlen Medical Nuclide Products Product Portfolio
  120. 7.20.5 Eckert & Ziegler Strahlen Recent Developments
  121. 7.21 Curium Pharma
  122. 7.21.1 Curium Pharma Company Information
  123. 7.21.2 Curium Pharma Business Overview
  124. 7.21.3 Curium Pharma Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Curium Pharma Medical Nuclide Products Product Portfolio
  126. 7.21.5 Curium Pharma Recent Developments
  127. 7.22 Cardinal Health
  128. 7.22.1 Cardinal Health Company Information
  129. 7.22.2 Cardinal Health Business Overview
  130. 7.22.3 Cardinal Health Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Cardinal Health Medical Nuclide Products Product Portfolio
  132. 7.22.5 Cardinal Health Recent Developments
  133. 7.23 Bracco Imaging
  134. 7.23.1 Bracco Imaging Company Information
  135. 7.23.2 Bracco Imaging Business Overview
  136. 7.23.3 Bracco Imaging Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  137. 7.23.4 Bracco Imaging Medical Nuclide Products Product Portfolio
  138. 7.23.5 Bracco Imaging Recent Developments
  139. 7.24 Aurobindo Pharma
  140. 7.24.1 Aurobindo Pharma Company Information
  141. 7.24.2 Aurobindo Pharma Business Overview
  142. 7.24.3 Aurobindo Pharma Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  143. 7.24.4 Aurobindo Pharma Medical Nuclide Products Product Portfolio
  144. 7.24.5 Aurobindo Pharma Recent Developments
  145. 7.25 ANSTO
  146. 7.25.1 ANSTO Company Information
  147. 7.25.2 ANSTO Business Overview
  148. 7.25.3 ANSTO Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  149. 7.25.4 ANSTO Medical Nuclide Products Product Portfolio
  150. 7.25.5 ANSTO Recent Developments
  151. 7.26 Acrotech Biopharma.
  152. 7.26.1 Acrotech Biopharma. Company Information
  153. 7.26.2 Acrotech Biopharma. Business Overview
  154. 7.26.3 Acrotech Biopharma. Medical Nuclide Products Revenue and Gross Margin (2021-2026)
  155. 7.26.4 Acrotech Biopharma. Medical Nuclide Products Product Portfolio
  156. 7.26.5 Acrotech Biopharma. Recent Developments
8 North America
  1. 8.1 North America Medical Nuclide Products Revenue (2021-2032)
  2. 8.2 North America Medical Nuclide Products Revenue by Type (2021-2032)
  3. 8.2.1 North America Medical Nuclide Products Revenue by Type (2021-2026)
  4. 8.2.2 North America Medical Nuclide Products Revenue by Type (2027-2032)
  5. 8.3 North America Medical Nuclide Products Revenue Share by Type (2021-2032)
  6. 8.4 North America Medical Nuclide Products Revenue by Application (2021-2032)
  7. 8.4.1 North America Medical Nuclide Products Revenue by Application (2021-2026)
  8. 8.4.2 North America Medical Nuclide Products Revenue by Application (2027-2032)
  9. 8.5 North America Medical Nuclide Products Revenue Share by Application (2021-2032)
  10. 8.6 North America Medical Nuclide Products Revenue by Country
  11. 8.6.1 North America Medical Nuclide Products Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Medical Nuclide Products Revenue by Country (2021-2026)
  13. 8.6.3 North America Medical Nuclide Products Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Medical Nuclide Products Revenue (2021-2032)
  2. 9.2 Europe Medical Nuclide Products Revenue by Type (2021-2032)
  3. 9.2.1 Europe Medical Nuclide Products Revenue by Type (2021-2026)
  4. 9.2.2 Europe Medical Nuclide Products Revenue by Type (2027-2032)
  5. 9.3 Europe Medical Nuclide Products Revenue Share by Type (2021-2032)
  6. 9.4 Europe Medical Nuclide Products Revenue by Application (2021-2032)
  7. 9.4.1 Europe Medical Nuclide Products Revenue by Application (2021-2026)
  8. 9.4.2 Europe Medical Nuclide Products Revenue by Application (2027-2032)
  9. 9.5 Europe Medical Nuclide Products Revenue Share by Application (2021-2032)
  10. 9.6 Europe Medical Nuclide Products Revenue by Country
  11. 9.6.1 Europe Medical Nuclide Products Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Medical Nuclide Products Revenue by Country (2021-2026)
  13. 9.6.3 Europe Medical Nuclide Products Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Medical Nuclide Products Revenue (2021-2032)
  2. 10.2 China Medical Nuclide Products Revenue by Type (2021-2032)
  3. 10.2.1 China Medical Nuclide Products Revenue by Type (2021-2026)
  4. 10.2.2 China Medical Nuclide Products Revenue by Type (2027-2032)
  5. 10.3 China Medical Nuclide Products Revenue Share by Type (2021-2032)
  6. 10.4 China Medical Nuclide Products Revenue by Application (2021-2032)
  7. 10.4.1 China Medical Nuclide Products Revenue by Application (2021-2026)
  8. 10.4.2 China Medical Nuclide Products Revenue by Application (2027-2032)
  9. 10.5 China Medical Nuclide Products Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Medical Nuclide Products Revenue (2021-2032)
  2. 11.2 Asia Medical Nuclide Products Revenue by Type (2021-2032)
  3. 11.2.1 Asia Medical Nuclide Products Revenue by Type (2021-2026)
  4. 11.2.2 Asia Medical Nuclide Products Revenue by Type (2027-2032)
  5. 11.3 Asia Medical Nuclide Products Revenue Share by Type (2021-2032)
  6. 11.4 Asia Medical Nuclide Products Revenue by Application (2021-2032)
  7. 11.4.1 Asia Medical Nuclide Products Revenue by Application (2021-2026)
  8. 11.4.2 Asia Medical Nuclide Products Revenue by Application (2027-2032)
  9. 11.5 Asia Medical Nuclide Products Revenue Share by Application (2021-2032)
  10. 11.6 Asia Medical Nuclide Products Revenue by Country
  11. 11.6.1 Asia Medical Nuclide Products Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Medical Nuclide Products Revenue by Country (2021-2026)
  13. 11.6.3 Asia Medical Nuclide Products Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Medical Nuclide Products Revenue (2021-2032)
  2. 12.2 SAMEA Medical Nuclide Products Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Medical Nuclide Products Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Medical Nuclide Products Revenue by Type (2027-2032)
  5. 12.3 SAMEA Medical Nuclide Products Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Medical Nuclide Products Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Medical Nuclide Products Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Medical Nuclide Products Revenue by Application (2027-2032)
  9. 12.5 SAMEA Medical Nuclide Products Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Medical Nuclide Products Revenue by Country
  11. 12.6.1 SAMEA Medical Nuclide Products Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Medical Nuclide Products Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Medical Nuclide Products Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst